Investigational drug · Phase 3
DISC-1459
Also called: Bitopertin, RO4917838
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Erythropoietic Protoporphyria, Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "DISC-1459"
First trial start
2023
Aug 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DISC-1459", any sponsor or status.
Conditions studied
As listed on its trial records.
- Erythropoietic Protoporphyria
- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)
Approved drugs for the same conditions: Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "DISC-1459" as an intervention, largest first.
- HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLPPivotal-lookingEnrolling by invitation
Disc Medicine, IncIndustry
NCT05883748 · 230 participants (planned) · Start Aug 31, 2023 · Primary completion Jun 2028
Drug: DISC-1459; DISC-1459 · For: Erythropoietic Protoporphyria
Sites: Birmingham, Alabama; San Francisco, California; Miami, Florida · 26 sites in all
- Study of Bitopertin in Participants With EPP or XLP (APOLLO)Pivotal-lookingCompleted
Disc Medicine, IncIndustry
NCT06910358 · 183 participants · Start Apr 4, 2025 · Primary completion Sep 8, 2026
Drug: Placebo; DISC-1459 · For: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)
Sites: Huntington Beach, California; San Francisco, California; Miami, Florida · 27 sites in all
Disc Medicine, IncIndustry
NCT05308472 · 75 participants · Start Oct 31, 2022 · Primary completion Feb 20, 2024
Drug: DISC-1459; DISC-1459 and 1 more · For: Erythropoietic Protoporphyria
Sites: Birmingham, Alabama; San Francisco, California; Miami, Florida · 9 sites in all
Wake Forest University Health SciencesAcademic, hospital or other
NCT07123363 · 0 participants · Start Jan 2026 · Primary completion Dec 2035
Drug: bitopertin · For: Protoporphyria
Disc Medicine, IncIndustry
NCT07603401
Drug: DISC-1459 · For: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)
Sites: Miami, Florida; Boston, Massachusetts; Detroit, Michigan · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Glycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex.
Graf M, Ponserre M, Sadeh S, et al. · Neuropharmacology 2026
- Study Design and Baseline Characteristics of APOLLO: A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X-Linked Protoporphyria.
Yeung A, Amster M, Anderson KE, et al. · J Dermatol 2026
- Comment on 'An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria'.
Xiao Z, Li R, Tan Y · Clin Exp Dermatol 2026
- An interpretable consensus pipeline for candidate dopamine D2 receptor ligands.
Mtambo S, Kumalo HM, Ssemakalu CC · In Silico Pharmacol 2026
- A Role for Glycine Transporter-2 Inhibitors in Regulating Accumbal Dopamine Levels and Voluntary Alcohol Intake in Rats.
Olsson Y, Danielsson K, Domi A, et al. · Alcohol Clin Exp Res (Hoboken) 2026
- Results from the first clinical trial of bitopertin for steroid-relapsed/refractory Diamond-Blackfan anemia.
Young DJ, Machado TR, Cowling BC, et al. · Blood Red Cells Iron 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.